SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury – Pharmacy Times

1. SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury  Pharmacy Times
2. SGLT2 Inhibitors Show Superior Kidney Outcomes Compared to GLP-1 Receptor Agonists: JAMA  Medical Dialogues
3. Superior renal benefits of SGLT2 inhibitors in type 2 diabetes highlighted in comparative study  Hospital Healthcare Europe
4. GLP-1 Diabetes Drugs Linked to Increased Risk of Kidney Side Effects  AboutLawsuits.com
5. SGLT2 Inhibitors Linked to Improved Kidney Outcomes in Type 2 Diabetes  European Medical Journal

Source link